Novo's rumored CEO heir suddenly out of a job

Novo Nordisk ($NVO) COO Kåre Schultz has long been considered the heir apparent to CEO Rebien Sørensen, whenever he retires. And so it came as a bit of a shock when the company unceremoniously disclosed his departure Thursday with a single line at the bottom of its quarterly financial release. "The board," Sørensen told analysts, "decided it wanted to have greater visibility on our corporate launches in key markets. As a consequence, the COO job disappeared." Story

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.